Listen to three leading experts discussing the recent advances in timely, biomarker-guided diagnosis and how current and emerging intravenous and subcutaneous disease-modifying therapies may impact clinical practice in the future and enable treatment personalization based on the underlying pathology of Alzheimer’s disease
The experts
Dr Soo Borson, Keck USC School of Medicine, Los Angeles, CA, USA
Dr Clifford Singer, Northern Light Acadia Hospital, Bangor, ME, USA
Dr Frederick Ketchum, University of Wisconsin-Madison, Madison, WI, USA
This touchPODCAST is for HCPs outside of the UK only.
This activity is funded by an independent medical education grant from Eisai Inc.
Jointly provided by Partners for Advancing Clinical Education and touchIME in collaboration with the Gerontological Society of America (GSA).
Podden och tillhörande omslagsbild på den här sidan tillhör
touchpodcast. Innehållet i podden är skapat av touchpodcast och inte av,
eller tillsammans med, Poddtoppen.
